KYNTRA BIO, INC. ·
KYNB 8-K 2026-10-01
KYNTRA BIO, INC. (KYNB) 8-K dated 2026-10-01 — accession 0001193125-26-409819.
KYNTRA BIO, INC. (KYNB) common stock.
KYNTRA BIO, INC. filed a 8-K on 2026-10-01. Accession 0001193125-26-409819.
This 8-K covers: Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.
Latest reported KYNB revenue for 2025-12-31 was $6.4M. Net income was $183.5M. Revenue was down 95.6% from 2023-12-31 to 2025-12-31. KYNB currently screens at market cap $8.3M.
Not investment advice. The KYNB SEC hub lists recent forms. The stock page is the research view.